CytomX Therapeutics Inc
NASDAQ:CTMX

Watchlist Manager
CytomX Therapeutics Inc Logo
CytomX Therapeutics Inc
NASDAQ:CTMX
Watchlist
Price: 2.38 USD -0.42% Market Closed
Market Cap: 375m USD

Relative Value

The Relative Value of one CTMX stock under the Base Case scenario is 0.3 USD. Compared to the current market price of 2.38 USD, CytomX Therapeutics Inc is Overvalued by 88%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CTMX Relative Value
Base Case
0.3 USD
Overvaluation 88%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
73
vs Industry
91
Median 3Y
2.8
Median 5Y
7.9
Industry
7.5
Forward
4.2
vs History
15
vs Industry
13
Median 3Y
-1.6
Median 5Y
-3.9
Industry
23.6
Forward
-11
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-4
Industry
20.2
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-3.9
Industry
22.9
vs History
17
vs Industry
Median 3Y
-3.3
Median 5Y
3.7
Industry
2.8
vs History
47
vs Industry
85
Median 3Y
0.7
Median 5Y
2
Industry
7.7
Forward
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
vs History
9
vs Industry
20
Median 3Y
0
Median 5Y
-0.9
Industry
4.9
Forward
15.2
vs History
12
vs Industry
17
Median 3Y
0
Median 5Y
-0.8
Industry
4.9
Forward
-62.1
vs History
vs Industry
25
Median 3Y
-0.7
Median 5Y
-1.1
Industry
5.4
vs History
vs Industry
21
Median 3Y
-0.7
Median 5Y
-1.1
Industry
4
vs History
15
vs Industry
71
Median 3Y
2.4
Median 5Y
3.5
Industry
5.1

Multiples Across Competitors

CTMX Competitors Multiples
CytomX Therapeutics Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
CytomX Therapeutics Inc
NASDAQ:CTMX
375m USD 2.5 9 7.8 8.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 139 238 -162 258.7 -197 033.9 -194 785.5
US
Abbvie Inc
NYSE:ABBV
338.1B USD 5.9 81.4 15.5 22.9
US
Amgen Inc
NASDAQ:AMGN
160.4B USD 4.7 27 14.5 23.9
US
Gilead Sciences Inc
NASDAQ:GILD
135.5B USD 4.7 22.7 9.9 13.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD 10.7 -120.4 25.6 26.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 063.6 -526.6 -573.4 -558.1
AU
CSL Ltd
ASX:CSL
123.9B AUD 5.3 29.3 18 22.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.5B USD 4.2 13.2 11.8 13.3
US
Seagen Inc
F:SGT
39.3B EUR 19.9 -61 -65.7 -59.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
42.3B USD 18 -156.9 -704 -352.8
P/E Multiple
Earnings Growth PEG
US
CytomX Therapeutics Inc
NASDAQ:CTMX
Average P/E: 30.4
9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 258.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.4
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
27
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.7
189%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -120.4 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -526.6 N/A N/A
AU
CSL Ltd
ASX:CSL
29.3
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -156.9 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
CytomX Therapeutics Inc
NASDAQ:CTMX
Average EV/EBITDA: 14.7
7.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 033.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.5
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.6
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -573.4 N/A N/A
AU
CSL Ltd
ASX:CSL
18
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -704 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
CytomX Therapeutics Inc
NASDAQ:CTMX
Average EV/EBIT: 18.7
8.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 785.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.9
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.6
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.1 N/A N/A
AU
CSL Ltd
ASX:CSL
22.5
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -352.8 N/A N/A